Human Anti-EGFR Recombinant Antibody (clone C225) (CAT#: PABL-462)
Recombinant Human Antibody (C225) is capable of binding to EGFR, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-EGFR mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-EGFR proteins mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition.
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.
Figure 1 Inhibition of VEGF (A), IL-8 (A), and bFGF (B) steady-state mRNA expression by C225 mAb in vitro.
Cells were cultured in the presence of or absence of MAb C225. mRNA was extracted after 48 h of treatment and analyzed by Northern blotting. Using image densitometry, the mRNA expression of untreated cells was assumed to be 100% of potential expression for these cells. Treatment with C225 down-regulated VEGF, IL-8, and bFGF mRNA expression in a dose-dependent fashion. β-actin served as a control for loading (exposure, 30 min).
Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., ... & Dinney, C. P. (1999). Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clinical Cancer Research, 5(2), 257-264.
Figure 2 Immunohistochemical staining of MAb C225-treated human TCC tumors growing in the bladders of athymic nude mice.
MAb C225-treated tumors (after 3 weeks and 5 weeks of therapy) and control tumors were stained with CD31 antibodies directed against mouse endothelial cells (A–C). Note the increased vessel density in the control tumors (A) and the 3-week C225-treated tumors (B) compared with that of the 5-week C225-treated specimen (C). Immunostaining for VEGF (D–F), IL-8 (G–I), and bFGF (J–L) is higher in the control tumors (D, G, and J) than in the MAb C225-treated specimens (E, F, H, I, K, and L) at 3 weeks and 5 weeks. Note that the down-regulation of VEGF, IL-8, and bFGF precedes the inhibition of angiogenesis.
Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., ... & Dinney, C. P. (1999). Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clinical Cancer Research, 5(2), 257-264.
Specifications
- Immunogen
- Human epidermal growth factor receptor
- Host Species
- Human
- Type
- Human IgG
- Specificity
- Human EGFR
- Species Reactivity
- Human
- Clone
- C225
- Applications
- FC
Product Property
- Purity
- >95% as determined by SDS-PAGE and HPLC analysis
- Concentration
- Please refer to the vial label for the specific concentration.
- Storage
- Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Target
- Alternative Names
- EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog;
- Gene ID
- 1956
- UniProt ID
- P00533
Related Resources
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Clone C225"
See other products for "EGFR"
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-228CL | Anti-Human EGFR Recombinant Antibody (ABT-806) | WB, IHC | Antibody |
TAB-297MZ | Anti-Human EGFR Recombinant Antibody (H225) | ELISA, WB | Humanized antibody |
TAB-298MZ | Anti-Human EGFR Recombinant Antibody (Hu225) | ELISA, WB | Humanized antibody |
TAB-300MZ | Human Anti-EGFR Recombinant Antibody (TAB-300MZ) | ELISA | Humanized IgG |
PABX-052 | Recombinant Human Anti-EGFR Antibody (PABX-052) | WB, ELISA, FuncS, IB, FC, SPR, Apop | IgG |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for PABL-462. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: FuncS, IF, Neut, ELISA, FC, IP, ICC
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: FC, IP, ELISA, Neut, FuncS, IF, ICC
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: WB, FC, IP, ELISA, Neut, FuncS, IF
Application: ELISA
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: ELISA, Inhib, FuncS
Application: ELISA, IF, Block, FuncS
Application: ELISA, Block, WB, FC, IP
Application: ELISA, IHC, IF, IP
Application: WB, IHC-Fr, IHC-P, ICC, IF
For Research Use Only. Not For Clinical Use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.